



Final Appraisal Recommendation

Advice No: 0218 – February 2018

Lopinavir/ritonavir (Kaletra®) 80 mg/20 mg oral solution

Limited submission by AbbVie Ltd

Recommendation of AWMSG

Lopinavir/ritonavir (Kaletra®) is recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected children aged from 14 days to less than 2 years old.

Additional note(s):

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 3357), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	AbbVie Ltd
Date of first issue	February 2018
Last reviewed	March 2021

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group Final Appraisal Recommendation – 0218:
Lopinavir/ritonavir (Kaletra®) 80 mg/20 mg oral solution. February 2018.